Last 12 months
Inside the activity.
0 purchase rows · 204 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 17 |
| Dec 2025 | 0 | 26 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 8 |
| Jun 2026 | 0 | 32 |
| Jul 2026 | 0 | 64 |
| Aug 2026 | 0 | 27 |
| Sep 2026 | 0 | 20 |
| Oct 2026 | 0 | 5 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2020 Filed Dec 30, 2020 21:34 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 200 | $249.88 | $49,975.00 |
DisclosureSEC source: 0001651308-20-000238 · wf-form4_160936407998605.xml · nonDerivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $249.80 to $249.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:34 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 200 | $247.98 | $49,595.00 |
DisclosureSEC source: 0001651308-20-000238 · wf-form4_160936407998605.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.90 to $248.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:34 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 300 | $246.02 | $73,806.99 |
DisclosureSEC source: 0001651308-20-000238 · wf-form4_160936407998605.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.90 to $246.15, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:34 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 200 | $244.90 | $48,979.04 |
DisclosureSEC source: 0001651308-20-000238 · wf-form4_160936407998605.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.75 to $245.09, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:34 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionAmerican Depositary Shares | 1,500 | $29.49 | $44,235.00 |
DisclosureSEC source: 0001651308-20-000238 · wf-form4_160936407998605.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| December 18, 2020 Filed Dec 19, 2020 02:25 UTC |
AMGEN INC10% owner
|
GrantAmerican Depositary Shares | 25,762 | $260.95 | $6,722,503.73 |
DisclosureSEC source: 0000899243-20-034573 · doc4.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,778,273 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F2 · price: The price reported is an average price. These American Depositary Shares ("ADSs") were purchased at prices ranging from $256.72 to $264.92 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. F3 · balance_after: As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 244,117,549 Ordinary Shares. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 02:18 UTC |
AMGEN INC10% owner
|
GrantAmerican Depositary Shares | 74,624 | $260.54 | $19,442,507.11 |
DisclosureSEC source: 0000899243-20-034372 · doc4.xml · nonDerivative · entry 3 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,752,511 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F4 · price: The price reported is an average price. These ADSs were purchased at prices ranging from $254.135 to $265.00 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. F5 · balance_after: As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 243,782,643 Ordinary Shares. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 02:18 UTC |
AMGEN INC10% owner
|
GrantAmerican Depositary Shares | 85,573 | $248.26 | $21,244,455.67 |
DisclosureSEC source: 0000899243-20-034372 · doc4.xml · nonDerivative · entry 2 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,677,887 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F3 · price: The price reported is an average price. These ADSs were purchased at prices ranging from $241.29 to $250.17 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:45 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
GiftOrdinary Shares | 165,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000234 · wf-form4_160824149903220.xml · nonDerivative · entry 1 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,703,162 F1 · price: Bona fide gift(s) of shares which are exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 02:18 UTC |
AMGEN INC10% owner
|
GrantAmerican Depositary Shares | 67,941 | $239.31 | $16,258,722.92 |
DisclosureSEC source: 0000899243-20-034372 · doc4.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,592,314 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F2 · price: The price reported is an average price. These American Depositary Shares ("ADSs") were purchased at prices ranging from $232.86 to $241.845 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,600,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · derivative · entry 13 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831,000 Underlying: Ordinary Shares · 2,600,000 shares Expires 2025-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F13 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 15, 2016, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon a sale event or certain termination events. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 700 | $232.19 | $162,532.02 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · nonDerivative · entry 12 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.97 to $232.58, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 17,456 | $231.11 | $4,034,303.29 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · nonDerivative · entry 11 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $230.89 to $231.87, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 24,842 | $230.51 | $5,726,244.96 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · nonDerivative · entry 10 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,156 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.88 to $230.87, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 9,752 | $229.18 | $2,234,962.38 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · nonDerivative · entry 9 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,998 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.82 to $229.79, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 5,885 | $228.23 | $1,343,126.49 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · nonDerivative · entry 8 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,750 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.80 to $228.795, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 400 | $228.10 | $91,240.00 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · nonDerivative · entry 7 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,635 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 7,500 | $227.72 | $1,707,919.50 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · nonDerivative · entry 6 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,035 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.03 to $228.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 15,062 | $227.08 | $3,420,268.42 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · nonDerivative · entry 5 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,535 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $226.77 to $227.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 6,203 | $226.40 | $1,404,377.19 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · nonDerivative · entry 4 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,597 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.77 to $226.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 4,100 | $225.24 | $923,479.90 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · nonDerivative · entry 3 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,800 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.75 to $225.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
Exercise / conversionAmerican Depositary Shares | 91,900 | $6.50 | $597,350.00 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · nonDerivative · entry 2 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
Exercise / conversionOrdinary Shares | 1,405,300 | $0.50 | $702,650.00 |
DisclosureSEC source: 0001651308-20-000233 · wf-form4_160815501734729.xml · nonDerivative · entry 1 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,573,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 22:09 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
GiftOrdinary Shares | 545,597 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000232 · wf-form4_160807018171872.xml · nonDerivative · entry 3 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 545,597 F3 · ownership.nature: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 22:09 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
GiftOrdinary Shares | 545,597 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000232 · wf-form4_160807018171872.xml · nonDerivative · entry 2 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,790,656 F2 · price: Bona fide gift of shares to the P&O Trust which is exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 22:09 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
GiftOrdinary Shares | 1,591,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000232 · wf-form4_160807018171872.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,336,253 F1 · price: Bona fide gift of shares to a private foundation which is exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:55 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
GiftOrdinary Shares | 1,244,542 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000231 · wf-form4_160798292322230.xml · nonDerivative · entry 3 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,244,542 F2 · ownership.nature: These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:55 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
GiftOrdinary Shares | 1,244,542 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000231 · wf-form4_160798292322230.xml · nonDerivative · entry 2 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,868,457 F1 · price: Bona fide gift(s) of shares which are exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:55 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
GiftOrdinary Shares | 88,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000231 · wf-form4_160798292322230.xml · nonDerivative · entry 1 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,112,999 F1 · price: Bona fide gift(s) of shares which are exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| December 04, 2020 Filed Dec 4, 2020 22:24 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
SaleAmerican Depositary Shares | 1,386,033 | $220.50 | $305,620,276.50 |
DisclosureSEC source: 0001638599-20-000941 · doc4_6945.xml · nonDerivative · entry 8 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,811,048 F10 · shares: 667 and Life Sciences entered into an underwriting agreement with an underwriter pursuant to which they sold 125,513 and 1,386,033 ADS, respectively to the underwriter at a price of $220.50 per ADS (net of underwriting discounts) in transactions that closed on December 4, 2020. F1 · ownership.nature: Ordinary Shares ("Ordinary Shares") of BeiGene, Ltd. (the "Issuer") are convertible into American Depositary Shares of the Issuer ("ADS") on a 13:1 basis. F7 · ownership.nature: As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Baker Brothers Life Sciences, L.P, ("Life Sciences", and together with 667, the "Funds"), Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F9 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F10 · ownership.nature: 667 and Life Sciences entered into an underwriting agreement with an underwriter pursuant to which they sold 125,513 and 1,386,033 ADS, respectively to the underwriter at a price of $220.50 per ADS (net of underwriting discounts) in transactions that closed on December 4, 2020. Read SEC document |
| December 04, 2020 Filed Dec 4, 2020 22:24 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
SaleAmerican Depositary Shares | 125,513 | $220.50 | $27,675,616.50 |
DisclosureSEC source: 0001638599-20-000941 · doc4_6945.xml · nonDerivative · entry 7 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 979,003 F10 · shares: 667 and Life Sciences entered into an underwriting agreement with an underwriter pursuant to which they sold 125,513 and 1,386,033 ADS, respectively to the underwriter at a price of $220.50 per ADS (net of underwriting discounts) in transactions that closed on December 4, 2020. F1 · ownership.nature: Ordinary Shares ("Ordinary Shares") of BeiGene, Ltd. (the "Issuer") are convertible into American Depositary Shares of the Issuer ("ADS") on a 13:1 basis. F6 · ownership.nature: As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F9 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F10 · ownership.nature: 667 and Life Sciences entered into an underwriting agreement with an underwriter pursuant to which they sold 125,513 and 1,386,033 ADS, respectively to the underwriter at a price of $220.50 per ADS (net of underwriting discounts) in transactions that closed on December 4, 2020. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:50 UTC |
Glazer Donald W.Director
|
GiftOrdinary Shares | 589,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000230 · wf-form4_160746423986620.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,907,829 F1 · price: Bona fide gifts of shares which are exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionShare Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · derivative · entry 14 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,075 Underlying: Ordinary Shares · 19,500 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F8 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 96 | $285.05 | $27,364.80 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · nonDerivative · entry 13 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 100 | $278.92 | $27,892.00 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · nonDerivative · entry 12 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 100 | $277.22 | $27,722.00 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · nonDerivative · entry 11 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 100 | $275.45 | $27,545.00 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · nonDerivative · entry 10 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 100 | $269.05 | $26,905.00 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · nonDerivative · entry 9 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 300 | $266.75 | $80,025.00 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · nonDerivative · entry 8 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.44 to $267.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 200 | $264.50 | $52,900.00 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · nonDerivative · entry 7 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 796 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.46 to $264.54, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 100 | $263.28 | $26,328.00 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · nonDerivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 200 | $262.06 | $52,411.00 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,096 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.71 to $262.40, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 100 | $260.06 | $26,006.00 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,296 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 104 | $256.00 | $26,623.72 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,396 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.18 to $256.03, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:01 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionAmerican Depositary Shares | 1,500 | $29.49 | $44,235.00 |
DisclosureSEC source: 0001651308-20-000223 · wf-form4_160694645589206.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:44 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionShare Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001651308-20-000198 · wf-form4_160435340260982.xml · derivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,575 Underlying: Ordinary Shares · 19,500 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F6 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:44 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 100 | $301.51 | $30,151.00 |
DisclosureSEC source: 0001651308-20-000198 · wf-form4_160435340260982.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:44 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 139 | $300.70 | $41,797.74 |
DisclosureSEC source: 0001651308-20-000198 · wf-form4_160435340260982.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $300.34 to $300.86, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:44 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 1,261 | $299.88 | $378,144.27 |
DisclosureSEC source: 0001651308-20-000198 · wf-form4_160435340260982.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $299.30 to $300.12, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:44 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionAmerican Depositary Shares | 1,500 | $29.49 | $44,235.00 |
DisclosureSEC source: 0001651308-20-000198 · wf-form4_160435340260982.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.